Keystone eSymposia Logo

Precision Oncology: Translating Discovery to the Clinic

June 21-24, 2021 | 9:00AM EDT | 1:00PM UTC | 3:00PM CEST*
*Program is in development and subject to change


The live portion of this conference has concluded and all presentations are now available for purchase on demand. Registrants to the live event may access this content anytime for up to 9 months following the event.

 Free Access to On Demand Content to Scientists from Low-and Middle-Income Countries

Keystone Symposia welcomes the global scientific community and aims to connect researchers within and across disciplines to accelerate the advancement of biomedical and life sciences. This form may be used for scientists from low- and middle-income countries of all career stages to determine eligibility and request free access to scientific content presented during recent eSymposia events. If eligible, you will be sent an access code for the On Demand content of the eSymposia event(s) of interest.

Apply Here

The discovery of genomic and epigenetic alterations in individual cancers has led to a plethora of precision medicine innovations and therapeutic successes in oncology. Accordingly, cancer treatments have migrated away from the “one size fits all” approach. However, even as precision medicine is becoming more multi-disciplinary, progress is still hindered by insufficient collaboration between basic researchers, drug development programs, and physician scientists with broad expertise across cancer biology, genomics and other relevant fields.

Therefore, this conference will bring together diverse experts from academic, pharma/biotech, medical and government sectors to discuss current challenges and future directions in precision oncology. In particular, the meeting will foster crosstalk between clinicians, cancer biologists and genomic scientists to identify and address key knowledge gaps that limit the advancement of new precision therapies. This conference program will cover topics such as novel genomic insights, therapeutically promising mechanisms and cancer drug targets, recent translational breakthroughs, and the incorporation of new diagnostic tools as companions to new precision treatments. 

The program will emphasize leading-edge advances in “reverse translation” technologies, such as liquid biopsies and single cell genomics, in addition to innovative, first-in-class approaches to novel therapeutics. Ultimately, the goal of the conference is to forge new collaborations across scientific and clinical boundaries, to advance the next generation of precision medicines against cancer.

Apply Here for Free On Demand Access


Regular Registration Rate: $275 USD
Student Registration Rate: $150 USD


Abstract Submission
‣ For Short Talk Consideration: Passed
‣ For Poster Booth: Passed
ePoster / SciTalk Submission: Passed
Financial Aid Application: Passed

*Abstract submission is required in order to submit an ePoster and/or Scitalk


Program Details

Keynote Speaker

Charles Sawyers

Charles L. Sawyers, MD
Johns Hopkins University School of Medicine

Speaking at this eSymposia

Nicola Aceto

ETH Zürich, Switzerland

Valsamo Anagnostou

Johns Hopkins University School of Medicine, USA

Scott A. Armstrong

Dana-Farber Cancer Institute, USA

Alberto Bardelli

University of Torino, Italy

Jaclyn A. Biegel

Children's Hospital Los Angeles and Keck School of Medicine of USC, USA

Jason S. Carroll

Cancer Research UK, University of Cambridge, UK

Arvin C. Dar

Icahn School of Medicine at Mount Sinai, USA

Lori Friedman

ORIC Pharmaceuticals, USA

Todd R. Golub

Broad Institute, USA

Timothy Heffernan

MD Anderson Cancer Center, USA

Priti Hegde

Foundation Medicine, USA

John V. Heymach

University of Texas MD Anderson Cancer Center, USA

Klaus P. Hoeflich

Blueprint Medicines, USA

Russell W. Jenkins

Massachusetts General Hospital, USA

Cigall Kadoch

Dana-Farber Cancer Institute, Harvard Medical School, USA

Jessica J. Lin

Massachusetts General Hospital, USA

Scott W. Lowe

Memorial Sloan Kettering Cancer Center, USA

Elaine R. Mardis

Nationwide Children's Hospital, USA

Martin McMahon

University of Utah School of Medicine, USA

Trudy G. Oliver

Huntsman Cancer Institute, USA

Elli Papaemmanuil

Memorial Sloan Kettering Cancer Center, USA

Neal Rosen

Memorial Sloan-Kettering Cancer Center, USA

Alice T. Shaw

Massachusetts General Hospital Cancer Center, USA

Gromoslaw A. Smolen

Celsius Therapeutics, USA

Naoko Takebe

NCI, National Institutes of Health, USA

Nikhil Wagle

Dana-Farber Cancer Institute, USA

Christopher Vakoc

Cold Spring Harbor Laboratory, USA

Nir Yosef

University of California, Berkeley, USA







Additional Support



Funding for this conference was made possible (in part) by Grant No. [GRANT NUMBER - UPDATE] from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Media-in-Kind Support










The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.


This new virtual meeting format came out of difficult circumstances, but your commitment to scientific progress is what inspired us to launch Keystone eSymposia. In these virtual meetings, we are capturing the same innovative essence of our in-person meetings that you've all created as a scientific community.  Here, Debbie Johnson, our CEO, explains how we're going to do that.

Donate to Keystone Symposia

Donate to Keystone Symposia